An Evaluation of the Safety and Efficacy of TSND-201 for the Treatment of PTSD
NCT07836647
This study is recruiting at 6 US sites in 4 states, according to its ClinicalTrials.gov record last updated .
Summary
This study is evaluating the safety and efficacy of TSND-201 in adults with PTSD. Eligible participants will enter a 4-week Treatment Period where they will be randomized 1:1:1 to receive one of two doses of TSND-201 or placebo, once per week. Following the Treatment Period, participants will enter an 8-week Follow-up Period.
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- Post Traumatic Stress Disorder
Eligibility basics and study details
- Study type
- Interventional
- Phase
- Phase 3
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Sponsor
- Transcend Therapeutics
- Last updated on ClinicalTrials.gov
- November 2, 2026
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
Colorado · 1
- Mountain View Clinical Research · Denver, CO
Florida · 3
- Bradenton Research Center · Bradenton, FL
- CenExel Tampa · Tampa, FL
- K2 Medical Research Tampa · Tampa, FL
Georgia · 1
- CenExel Atlanta · Atlanta, GA
New Jersey · 1
- CenExel Marlton · Marlton, NJ
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.